Forendo Pharma’s HSD17B1-inhibitor drug candidate ... Forendo’s pipeline also includes fispemifene, a selective estrogen-receptor modulator that is a phase 2 asset for the treatment of ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...

The aromatase inhibitors have been widely incorporated into the adjuvant breast cancer care of postmenopausal women with estrogen and ... Aromatase inhibitor use is associated with an increased ...

while continuing the same CDK4/6 inhibitor. Camizestrant belongs to a class of drugs called selective estrogen receptor ...

This study reveals that Fe-doped boron nitride nanoparticles improve Anastrozole delivery, offering enhanced stability and targeted therapy for breast cancer.

DelveInsight's "VERZENIO Market Size, Forecast, and Market Insight Report" highlights the details around VERZENIO, which is a ...